A5008785159- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Cancer therapeutics and mechanisms
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Management of metastatic bone disease
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
- Glycosylation and Glycoproteins Research
- Immunodeficiency and Autoimmune Disorders
- Viral-associated cancers and disorders
The University of Texas MD Anderson Cancer Center
2016-2025
Peking Union Medical College Hospital
2023
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
Lymphoma Research Foundation
2009-2014
York University
2014
Winthrop-University Hospital
1996
Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM). However, studies have suggested this drug negatively affects subsequent stem cell collection. To investigate whether lenalidomide impairs mobilization and collection, we reviewed data for MM who underwent filgrastim. Predictors of failure were evaluated using logistic regression analysis. In 26 (9%) 302 patients, failed. Mobilization failed 25% had previously received lenalidomide, compared 4% not...
Summary Interleukin‐6 ( IL 6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid‐induced apoptosis. We therefore evaluated the efficacy safety of siltuximab, an anti‐ 6 monoclonal antibody, alone combination with dexamethasone, for patients relapsed or refractory who had ≥2 prior lines therapy, one which be bortezomib‐based. Fourteen initial received siltuximab alone, 10 whom dexamethasone added suboptimal response; 39 subsequent were treated...
Abstract BACKGROUND: The objective of this study was to review the outcome patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: authors retrospectively reviewed 84 SP who were diagnosed and treated at University Texas MD Anderson Cancer Center during 1988 2008. impact tumor anatomic site, size, presence serum urinary paraprotein diagnosis assessed on local control, survival, risk developing multiple myeloma (MM). RESULTS: Fifty‐nine (70%) had bone SP, 25...
The prognostic impact of additional copies chromosome 1q (1q + ) on outcomes newly-diagnosed multiple myeloma (NDMM) patients undergoing autologous transplantation (autoSCT) is unclear. We conducted a retrospective single-center analysis NDMM with 1q21 gain/amplification (3 or ≥4 1q, respectively) that received autoSCT between 2008-2018. 213 were included (79% gain; 21% amplification). most commonly used induction regimen was bortezomib, lenalidomide, and dexamethasone (41%). At day100...
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve durable response. In this retrospective study we included 1576 patients, 244 (15%) whom were long-term responders (LTR), defined as having progression-free survival (PFS) ≥8 years transplant. Patients in the LTR group younger than non-LTR (median age 58.4 vs. 59.5 years; p = 0.012), less...
Summary Signalling through the interleukin (IL)‐6 pathway induces proliferation and drug resistance of multiple myeloma cells. We therefore sought to determine whether IL‐6‐neutralizing monoclonal antibody siltuximab, formerly CNTO 328, could enhance activity melphalan, examine some mechanisms underlying this interaction. Siltuximab increased cytotoxicity melphalan in KAS‐6/1, INA‐6, ANBL‐6, RPMI 8226 human cell lines (HMCLs) an additive‐to‐synergistic manner, sensitized resistant 8226.LR5...
Abstract We retrospectively analyzed the outcomes of all consecutive patients with myeloma (n = 84) aged ≥70 years who had received autologous hematopoietic stem cell transplant (auto HCT) between July 1999 and June 2010 at our institution. The median age auto HCT was 72 years, number prior therapies 2.5 time from diagnosis to 10.2 months. conditioning regimen consisted melphalan 140 mg/m(2) in 10%, 180 25% 200 65% patients. day-100 non-relapse mortality 3%. overall response rate day 100 85%...
This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma.Patients ≥ grade 2 received 20 acupuncture treatments over 9 weeks.For the 19 evaluable patients, Functional Assessment Cancer Therapy/Gynecological Oncology Group-Neurotoxicity (FACT/GOG/NTX) mean (SD) scores improved significantly between baseline week 13 (20.8 [9.6] vs 13.2 [8.5], p = 0.0002)....
Although TRIzol is widely used for preservation and isolation of RNA, there suspicion that prolonged sample storage in may affect array-based gene expression profiling (GEP) through premature termination during reverse transcription.GEP on Illumina arrays compared paired aliquots (cryopreserved or stored TRIzol) primary samples multiple myeloma (MM) acute myeloid leukemia (AML). Data were analyzed at the "probe level" (a single consensus value) "bead (multiple measurements provided by...